The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Klara R KleinJennifer L R FreemanImogene DunnChris DvergstenM Sue KirkmanJohn B BuseCarmen Valcarcenull nullPublished in: Diabetes care (2021)
TTP399 lowers HbA1c and reduces hypoglycemia without increasing the risk of ketosis and should be further evaluated as an adjunctive therapy for the treatment of type 1 diabetes.